SH3809
/ Nanjing Sanhome Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 13, 2021
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=55; Recruiting; Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1